EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioactive IGF-I Concentrations in Children on GH Therapy

Lea Vilmann iD, Jakob Albrethsen iD, Jørgen Holm Petersen iD, Stine Agergaard Holmboe iD, Peter Christiansen, Katharina Maria Main iD, Line Cleemann iD, Kristian Horsman Hansen iD, Jan Frystyk iD, Casper P Hagen iD, Anders Juul iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Lea Vilmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Human Growth Hormone, Growth Disorders. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kirsten and Freddy Johansen Foundation, Novo Nordisk A/S, Centre on Endocrine Disruptors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monitoring IGF-I concentration is recommended during GH therapy in children. Supranormal levels of total IGF-I have raised concerns of long-term risks.

Aim

To evaluate bioactive and total IGF-I in healthy and in GH-treated children and adolescents. Materials and methods A reference population of 570 children (59% girls) from the Copenhagen Puberty Study III and 126 short children (36% girls) with GH deficiency (GHD) and other non-GHD conditions. We established pediatric, sex-specific reference ranges of serum concentrations of bioactive IGF-I (KIRA) and compared with total IGF-I and IGF-I/IGFBP-3 molar ratio (iSYS) and total IGF-I, -II, IGFBP-3, and acid labile subunit (liquid chromatography-tandem mass spectrometry) in a subgroup. Further, we compared IGF-I bioactivity with total IGF-I, IGFBP-3 (iSYS) and IGF-I/IGFBP-3 molar ratio during GH therapy.

Results

Bioactive IGF-I increased with age in healthy children and correlated positively with total IGF-I and IGF-I/IGFBP-3 in healthy males (r = 0.61 and r = 0.57; P < .001) and females (r = 0.58 and r = 0.59; P < .001) and with IGF-I, BP-3, and acid labile subunit (liquid chromatography-tandem mass spectrometry) (r = 0.56, r = 0.29, and r = 0.38; P < .001). Bioactive IGF-I and IGF-II (r = -0.29; P < .001) correlated negatively. In 13% (17/126) of the patients, bioactive IGF-I was above +2SD, whereas total IGF-I was above +2SD in 25% (32/126) patients. Nine patients had both total and bioactive IGF-I above +2SD. In the non-GHD groups, bioactive IGF-I SDS were lower than IGF-I SDS (P = .015).

Conclusion

Bioactive IGF-I was within reference ranges in the majority of GH-treated children. Monitoring bioactive IGF-I may help optimize GH dosing in specific patient subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like Growth Factor IHuman Growth HormoneGrowth DisordersHumansFemaleMaleChildAdolescentInsulin-Like Growth Factor Binding Protein 3Reference ValuesChild, PreschoolInsulin-Like Growth Factor II

Stichwörter der Autor:innen

GH therapyIGF-IIGFBP-3LC-MS/MSbioactive IGF-IrhGH

Substanzen

Insulin-Like Growth Factor IHuman Growth HormoneInsulin-Like Growth Factor Binding Protein 3IGF1 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor II

Autor:innen und Institutionen

  • Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen 2100, Denmark.
  • The International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark.
  • Section of Biostatistics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen 2200, Denmark.
  • Molecular Endocrinology Unit, KMEB, Department of Endocrinology, Odense University Hospital, Odense M 5230, Denmark.
  • OPEN Lab, Department of Endocrinology, Odense University Hospital, Odense 5230, Denmark.

ORCID-Profile: Lea Vilmann, Jakob Albrethsen, Jørgen Holm Petersen, Stine Agergaard Holmboe, Katharina Maria Main, Line Cleemann, Kristian Horsman Hansen, Jan Frystyk, Casper P Hagen, Anders Juul

Förderung

  • Kirsten and Freddy Johansen Foundation
  • Novo Nordisk A/S
  • Centre on Endocrine Disruptors
  • the Danish Environmental Protection Agency
  • OPEN Lab
  • Department of Endocrinology
  • Odense University Hospital
  • Research Council at Odense University Hospital

Zitieren

APA

Vilmann, L., Albrethsen, J., Petersen, J. H., Holmboe, S. A., Christiansen, P., Main, K. M., Cleemann, L., Hansen, K. H., Frystyk, J., Hagen, C. P., & Juul, A. (2025). Bioactive IGF-I Concentrations in Children on GH Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf566

Vancouver

Vilmann L, Albrethsen J, Petersen JH, Holmboe SA, Christiansen P, Main KM, et al. Bioactive IGF-I Concentrations in Children on GH Therapy. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf566

BibTeX
@article{Vilmann2025,
  author = {Vilmann, Lea and Albrethsen, Jakob and Petersen, Jørgen Holm and Holmboe, Stine Agergaard and Christiansen, Peter and Main, Katharina Maria and Cleemann, Line and Hansen, Kristian Horsman and Frystyk, Jan and Hagen, Casper P and Juul, Anders},
  title = {Bioactive IGF-I Concentrations in Children on GH Therapy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf566}
}
Kostenlos starten →